To include your compound in the COVID-19 Resource Center, submit it here.

Spinraza sales drive Biogen's guidance bump

Biogen Inc. (NASDAQ:BIIB) reported 2Q17 earnings, raised its full-year revenue guidance for 2017 and laid out a five-part growth strategy that emphasizes multiple sclerosis, spinal muscular atrophy (SMA) and neuroscience.

The company said faster-than-expected uptake of Spinraza nusinersen drove the decision to

Read the full 415 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE